Skip Navigation LinksHome > September 2012 - Volume 55 - Issue 3 > What Happened to WHI: Menopausal Hormonal Therapy in 2012
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e31825cab41
Office Gynecology

What Happened to WHI: Menopausal Hormonal Therapy in 2012

HANSEN, KEITH A. MD*; EYSTER, KATHLEEN M. PhD

Collapse Box

Abstract

Menopause is characterized by amenorrhea for 1 year due to the cessation of ovarian function. The hormonal treatment of menopause has significantly altered since the publication of initial results from the Women’s Health Initiative continuous, combined, conjugated equine estrogen with medroxyprogesterone acetate study arm in 2002. Current studies suggest that treatment should be individualized and that the lowest dose of estrogen providing relief should be used for the shortest period of time in menopausal women who experience vasomotor symptoms or urogenital atrophy. Future studies into different delivery mechanisms such as transdermal applications and different agents, such as tibolone and raloxifene, will help refine the treatment of menopause.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.